A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

NCT04687072 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

207

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Immune Thrombocytopenia

Interventions

BIOLOGICAL: Efgartigimod PH20 SC
OTHER: Placebo PH20 SC

Sponsor

argenx